Photo: open.spotify.com
Apr 21, 2026, 14:44
Continuing the Conversation on Factor VIII – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD), shared a post on LinkedIn:
”Continuing the conversation on Factor VIII!
As innovations such as emicizumab, rebalancing agents, and gene therapy continue to transform care, what is the place of FVIII today, and where is it heading next?”
Stay updated with Hemostasis Today.
-
Jun 17, 2026, 09:54Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
-
Jun 17, 2026, 09:47Nihal Mesmoudi: Inspired by Scientific Excellence at ICMES 2026
-
Jun 17, 2026, 09:26Nicolas Gendron: Join the Conversation on Antithrombotic Stewardship at ISTH 2026
-
Jun 17, 2026, 09:19Natalia Schütz: Translating Scientific Advances into Better Patient Outcomes
-
Jun 17, 2026, 05:21Finn Guo: Exploring Payment Mechanisms for Innovative Hemophilia Therapies
-
Jun 17, 2026, 04:59Wolfgang Miesbach: One-Time CRISPR Therapy Reduces Hereditary Angioedema Attacks by 87%
-
Jun 17, 2026, 04:47Ganesh Mohan: Celebrating the Heroes of Healthcare on World Blood Donor Day 2026
-
Jun 17, 2026, 04:31Ekrem Unal: Navigating the Budget Impact of Next-Generation Hemophilia Therapies in Turkey
-
Jun 17, 2026, 04:06Simon Zhao: Patient Community Promise 2025 Takes the Golden Snail Award at 14th China Rare Disease Summit